Weight LossClinical Trials
Pemvidutide
Also known as: ALT-801
A dual GLP-1/glucagon agonist built specifically to target and eliminate liver fat while driving 15%+ systemic weight loss.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~6–7 days
Typical Dose
Titrated weekly
Administration
Subcutaneous injection
Mechanism of Action
Leverages glucagon receptor activation to mobilize hepatic lipids while GLP-1 suppresses appetite, uniquely resolving MASH/NAFLD.
Key Research Areas
weight lossliverNAFLDMASH
Frequently Asked Questions
What is Pemvidutide?▾
A dual GLP-1/glucagon agonist built specifically to target and eliminate liver fat while driving 15%+ systemic weight loss.
How does Pemvidutide work?▾
Leverages glucagon receptor activation to mobilize hepatic lipids while GLP-1 suppresses appetite, uniquely resolving MASH/NAFLD.
What is the recommended dosage for Pemvidutide?▾
The typical research dosage is Titrated weekly, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Pemvidutide?▾
The half-life of Pemvidutide is approximately ~6–7 days. This affects dosing frequency and timing in research protocols.
Is Pemvidutide FDA approved?▾
Pemvidutide is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Pemvidutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.